Halozyme Therapeutics, Inc. Announces Upsize and Pricing of Private Offering of $625 Million of Convertible Senior Notes due 2028
SAN DIEGO, Aug. 15, 2022 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”), a leader…